The bipolar maze: A roadmap through translational psychopathology

Acta Psychiatrica Scandinavica

Volumn 129, Issue 5, 2014, Pages 323-327

  Vieta, Eduard ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; COMORBIDITY; EDITORIAL; GENETICS; HUMAN; MEDICATION COMPLIANCE; MENTAL DISEASE; NEUROIMAGING; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOTHERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EPIDEMIOLOGY; GENETIC ASSOCIATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PSYCHOLOGY; TRANSLATIONAL RESEARCH;

BIPOLAR DISORDER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EPIDEMIOLOGIC STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MAGNETIC RESONANCE IMAGING; PSYCHOPATHOLOGY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84898542844     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12270     Document Type: Editorial

References (72)

1. Post RM, Leverich GS, Kupka R et al. Increased parental history of bipolar disorder in the United States: association with early age of onset. Acta Psychiatr Scand 2014;129:375-382.
2. Baldessarini RJ, Tondo L, Visioli C. First-episode types in bipolar disorder: predictive associations with later illness. Acta Psychiatr Scand 2014;129:383-392.
3. Amerio A, Odone A, Liapis CC, Ghaemi SN. Diagnostic validity of comorbid bipolar disorder and obsessive-compulsive disorder: a systematic review. Acta Psychiatr Scand 2014;129:343-358.
4. Grande I, Magalhaes PV, Chendo I et al. Val66Met polymorphism and serum brain derived neurotrophic factor: an open-label trial. Acta Psychiatr Scand 2014;129:393-400.
5. Cipriani A, Barbui C, Rendell J, Geddes JR. Clinical and regulatory implications of active run-in phases in long-term studies for bipolar disorder. Acta Psychiatr Scand 2014;129:328-342.
6. Popovic D, Torrent C, Goikolea JM et al. Clinical implications ofpredominant polarity and the polarity index in bipolar disorder:a naturalistic study. Acta Psychiatr Scand 2014;129:366-374.
7. Sylvia LG, Reilly-Harrington NA, Leon AC et al. Medication adherence in a comparative effectiveness trial for bipolar disorder. Acta Psychiatr Scand 2014;129:359-365.
8. López-Muñoz F, Vieta E, Rubio G, García-García P, Alamo C. Bipolar disorder as an emerging pathology in the scientific literature: a bibliometric approach. J Affect Disord 2006;92:161-170.
9. Vieta E. Overcoming the current approach in bipolar disorder research: DSM-V and beyond. J Psychopharmacol 2008;22:406-407.
10. Vieta E. Bipolar units and programmes: are they really needed? World Psychiatry 2011;10:152.
11. Goodwin GM, Geddes JR. What is the heartland of psychiatry? Br J Psychiatry 2007;191:189-191.
12. Vieta E. Pros and cons of specialised care in bipolar disorder: aninternational perspective. Br J Psychiatry 2013;202:170-171.
13. Catalá-López F, Gènova-Maleras R, Vieta E, Tabarés-Seisdedos R. Theincreasing burden of mental and neurological disorders. Eur Neuropsychopharmacol 2013;23: 1337-1339.
14. Vieta E, Valentí M. Mixed states in DSM-5: implications for clinical care, education, and research. J Affect Disord 2013;148:28-36.
15. Vieta E, Grunze H, Azorin JM, Fagiolini A. Phenomenology of manic episodes according to the presence or absence of depressive features as defined in DSM-5: Results from the IMPACT self-reported online survey. J Affect Disord 2014;156:206-213.
16. Freedman R, Lewis DA, Michels R et al. The initial fieldtrials of DSM-5: new blooms and old thorns. Am J Psychiatry 2013;170:1-5.
17. Culberth BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry 2014;13:28-35.
18. Schumann G, Binder EB, Holte A et al. Stratified medicine for mental disorders. Eur Neuropsychopharmacol 2014;24:5-50.
19. Price FS, Morris JA. The genetics of bipolar disorder. BMJ 2013;346:1530.
20. Ferreira MA, Meng YA, Jones IR et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008;40:1056-1058.
21. Soeiro-De-souza MG, Bio DS, Dias VV, Vieta E, Machado-Vieira R, Moreno RA. The CACNA1C risk allele selectively impacts on executive function in bipolar typevI disorder. Acta Psychiatr Scand 2013;128:362-369.
22. Jiménez E, Arias B, Mitjans M et al. Association between GSK3β gene and increased impulsivity in bipolar disorder. Eur Neuropsychopharmacol 2014;24:510-518.
23. Jiménez E, Arias B, Mitjans M et al. Genetic variability at IMPA2, INPP1 and GSK3β increases the risk of suicidal behavior in bipolar patients. Eur Neuropsychopharmacol 2013;23:1452-1462.
24. Lim CS, Baldessarini RJ, Vieta E, Yucel M, Bora E, Sim K. Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. Neurosci Biobehav Rev 2013;37:418-435.
25. Canales-Rodríguez EJ, Pomarol-Clotet E, Radua J et al. Structural abnormalities in bipolar euthymia: A Multicontrast Molecular Diffusion Imaging Study. Biol Psychiatry 2013; doi: 10.1016/j.biopsych.2013.09.027. [Epub ahead of print].
26. Bechdolf A, Wood SJ, Nelson B et al. Amygdala and insula volumes prior to illness onset in bipolar disorder: a magnetic resonance imaging study. Psychiatry Res 2012;201:34-39.
27. Kim P, Thomas LA, Rosen BH et al. Differing amygdala responses to facial expressions in children and adults with bipolar disorder. Am J Psychiatry 2012;169:642-9.
28. Pomarol-Clotet E, Moro N, Sarró S et al. Failure of de-activation in the medial frontal cortex in mania: evidence for default mode network dysfunction in the disorder. World J Biol Psychiatry 2012;13:616-626.
29. Fernández-Corcuera P, Salvador R, Monté GC et al. Bipolar depressed patients show both failure to activate and failure to de-activate during performance of a working memory task. J Affect Disord 2013;148:170-8.
30. Vargas C, López-Jaramillo C, Vieta E. A systematic literature review of resting state network-functional MRI in bipolar disorder. J Affect Disord 2013;150:727-735.
31. Tiihonen J, Haukka J, Henriksson M et al. Premorbid intellectual functioning in bipolar disorder and schizophrenia: results from a cohort study of male conscripts. Am J Psychiatry 2005;162:1904-1910.
32. Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E. Cognitive impairment in bipolar disorder: neurodevelopment or neurodegeneration? An ECNP expert meeting report. Eur Neuropsychopharmacol 2008;18:787-793.
33. Torres IJ, Defreitas CM, Defreitas VG et al. Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. Psychol Med 2011;41:971-982.
34. Martínez-Arán A, Vieta E, Reinares M et al. Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004;161:262-270.
35. Bourne C, Aydemir Ö, Balanzá-Martínez V et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand 2013;128:149-162.
36. Vieta E, Popovic D, Rosa AR et al. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry 2013;28:21-29.
37. Dias VV, Brissos S, Frey BN, Andreazza AC, Cardoso C, Kapczinski F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord 2009;11:663-671.
38. Rosa AR, Singh N, Whitaker E et al. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychol Med 2014, doi: 10.1017/S0033291714000014. [Epub ahead of print].
39. López-Jaramillo C, Lopera-Vásquez J, Gallo A et al. Effects of recurrence on the cognitive performance of patients with bipolar I disorder: implications for relapse prevention and treatment adherence. Bipolar Disord 2010;12:557-567.
40. Bonnín CM, Torrent C, Goikolea JM et al. The impact of repeated manic episodes and executive dysfunction on work adjustment in bipolar disorder. Eur Arch Psychiatry ClinNeurosci 2014;264:247-254.
41. Martinez-Aran A, Torrent C, Tabares-Seisdedos R et al. Neurocognitive impairment in bipolar patients with and without history of psychosis. J Clin Psychiatry 2008;69:233-9.
42. Bonnín CM, Sánchez-Moreno J, Martínez-Arán A et al. Subthreshold symptoms in bipolar disorder: impact on neurocognition, quality of life and disability. J Affect Disord 2012;136:650-659.
43. Sanchez-Moreno J, Martinez-Aran A, Colom F et al. Neurocognitive dysfunctions in euthymic bipolar patients with and without prior history of alcohol use. J Clin Psychiatry 2009;70:1120-1127.
44. Torrent C, Martinez-Arán A, Daban C et al. Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Compr Psychiatry 2011;52:613-22.
45. Vieta E. The influence of medications on neurocognition in bipolar disorder. Acta Psychiatr Scand 2009;120:414-415.
46. Dias VV, Balanzá-Martinez V, Soeiro-De-souza MG et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand 2012;126:315-331.
47. Martinez-Aran A, Vieta E, Torrent C et al. Functional outcome in bipolar disorder: the role of clinical and cognitive factors. Bipolar Disord 2007;9:103-13.
48. Bonnín CM, Martínez-Arán A, Torrent C et al. Clinical and neurocognitive predictors of functional outcome in bipolar euthymic patients: a long-term, follow-up study. J Affect Disord 2010;121:156-160.
49. Rosa AR, González-Ortega I, González-Pinto A et al. One-year psychosocial functioning in patients in the early vs. late stage of bipolar disorder. Acta Psychiatr Scand 2012;125:335-341.
50. Solé B, Bonnin CM, Torrent C et al. Neurocognitive impairment and psychosocial functioning in bipolar II disorder. Acta Psychiatr Scand 2012;125:309-317.
51. Reinares M, Papachristou E, Harvey P et al. Towards a clinical staging for bipolar disorder: defining patient subtypes based on functional outcome. J Affect Disord 2013;144:65-71.
52. Papakostas GI. Cognitive symptoms in patients with major depressive disorder and their implications for clinical practice. J ClinPsychiatry 2014;75:8-14.
53. Torrent C, Bonnincdel M, Martínez-Arán A et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry 2013;170:852-859.
54. Vieta E, Langosch JM, Figueira ML et al. Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). Int J Neuropsychopharmacol 2013;16:1719-1732.
55. Nivoli AM, Colom F, Pacchiarotti I et al. Treatment strategies according to clinical features in a naturalistic cohort study of bipolar patients: a principal component analysis of lifetime pharmacological and biophysic treatment options. Eur Neuropsychopharmacol 2013;23:263-275.
56. Nivoli AM, Colom F, Murru A et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord 2011;129:14-26.
57. Nivoli AM, Murru A, Goikolea JM et al. New treatment guidelines for acute bipolar mania: a critical review. J Affect Disord 2012;140:125-141.
58. Scott J, Colom F, Pope M, Reinares M, Vieta E. The prognostic role of perceived criticism, medication adherence and family knowledge in bipolar disorders. J Affect Disord 2012;142:72-76.
59. Jónsdóttir H, Opjordsmoen S, Birkenaes AB et al. Predictors of medication adherence in patients with schizophrenia and bipolar disorder. ActaPsychiatr Scand 2013;127:23-33.
60. Murru A, Pacchiarotti I, Amann BL, Vieta E, Colom F. Treatment adherence in bipolar I and schizoaffective disorder, bipolar type. J Affect Disord 2013; 151:1003-8.
61. Popovic D, Reinares M, Amann B, Salamero M, Vieta E. Number needed to treat analyses of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology 2011;213:657-667.
62. Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol 2012;22:339-346.
63. Alphs L, Berwaerts J, Turkoz I. Limited utility of number needed to treat and the polarity index for bipolar disorder to characterize treatment response. Eur Neuropsychopharmacol 2013;23:1597-1599.
64. Baldessarini RJ, Undurraga J, Vázquez GH et al. Predominant recurrence polarity among 928 adult international bipolar I disorder patients. Acta Psychiatr Scand 2012;125:293-302.
65. Popovic D, Reinares M, Scott J et al. Polarity index of psychological interventions in maintenance treatment of bipolar disorder. Psychother Psychosom 2013;82:292-298.
66. BALANCE investigators and collaborators, Geddes JR, Goodwin GM et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375: 385-95.
67. Goodwin FK. Rationale for long-term treatment of bipolar disorder and evidence for long-term lithium treatment. J Clin Psychiatry 2002;63(Suppl. 10):5-12.
68. Pacchiarotti I, Bond DJ, Baldessarini RJ et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry 2013;170:1249-1262.
69. Dean B, Moller HJ, Svensson TH et al. Problems and solutions to filling the drying drug pipeline for psychiatric disorders: a report from the inaugural 2012 CINP Think Tank. Int J Neuropsychopharmacol 2014;17:137-148.
70. Vieta E, Cruz N. Head to head comparisons as an alternative to placebo-controlled trials. Eur Neuropsychopharmacol 2012;22:800-803.
71. Scott J. Más allá de la psicosis: el retode la intervención precoz en los trastornos bipolares. Rev Psiquiatr Salud Ment (Barc.) 2012;5:1-4.
72. Vieta E, Phillips ML. Deconstructing bipolar disorder: a critical review of its diagnostic validity and a proposal for DSM-V and ICD-11. Schizophr Bull 2007;33:886-892.